Recombinant Human Ccl5 protein

Ccl5 (C-C motif chemokine ligand 5), also known as RANTES (Regulated on Activation, Normal T-cell Expressed and Secreted), is a small secreted protein belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting leukocytes, particularly T cells, monocytes, and eosinophils, to sites of inflammation or infection. Ccl5 interacts with cell surface receptors CCR1. CCR3. and CCR5. triggering intracellular signaling pathways that mediate cell migration, activation, and adhesion. Its involvement in inflammatory diseases, viral infections (notably HIV entry via CCR5 co-receptor), and cancer progression has made it a key focus of biomedical research.

Recombinant Ccl5 protein is produced using engineered expression systems, such as *E. coli*, yeast, or mammalian cells, ensuring high purity and bioactivity for experimental and therapeutic applications. This engineered form retains the native protein’s functional properties, enabling researchers to study its role in vitro and in vivo models. Recombinant Ccl5 is widely used to investigate immune cell chemotaxis, inflammatory responses, and tumor microenvironment interactions. Additionally, it serves as a tool to screen potential inhibitors or modulators targeting Ccl5-receptor interactions, with implications for treating autoimmune disorders, chronic inflammation, and HIV infection. Despite its pro-inflammatory nature, dysregulated Ccl5 expression has been linked to pathological conditions, highlighting the need for precise control in therapeutic strategies. Studies also explore its dual role in cancer—either promoting tumor immunity or supporting metastasis, depending on context—underscoring its complexity as a therapeutic target.